Keytruda (pembrolizumab) is an Immunotherapy Drug


Keytruda (pembrolizumab) is an immunotherapy drug developed by Merck & Co. It’s primarily known for its use in treating various forms of cancer, particularly those that are associated with certain genetic characteristics or that have shown responsiveness to immune checkpoint inhibitors.

Pleural mesothelioma is a type of cancer that affects the lining of the lungs (pleura) and is often associated with asbestos exposure. Treatment options for mesothelioma have traditionally been limited, and the disease can be challenging to manage.

The FDA has approved Keytruda for a small percentage of cases of pleural mesothelioma. Immunotherapy drugs like Keytruda work by blocking certain proteins that help cancer cells evade the immune system, thus allowing the immune system to target and destroy cancer cells more effectively.

Please note that developments in medical research and drug approvals can change over time. To get the most up-to-date and accurate information about the FDA’s approval of Keytruda for pleural mesothelioma, I recommend checking the FDA’s official website, or consulting with a medical professional.

November 4, 2023